Biweekly vs conventional trifluridine/tipiracil plus bevacizumab for refractory mCRC: The pragmatic ph 3 PRABITAS trial
#ESMO26 #ESMOAmbassadors
👉ORR: 2 vs 2%
👉 mPFS: 3.9 vs 3.9 mo
👉 mOS: 10.3 vs 11.3 mo
🧐similar efficacy, less toxicity, supports biweekly schedule
@myESMO @ASCO
156 views · 4 likes · 1 repost · 0 replies
Iparomlimab and tuvonralimab (QL1706) plus chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (R/M CC): Results from a double-blind, randomized, placebo-controlled phase
https://esmocongress.esmo.orgLong-term follow-up of telisotuzumab adizutecan (ABBV-400, Temab-A) in combination with bevacizumab (Bev) vs standard of care (SOC) in patients (pts) with 3L+ colorectal cancer (CRC): Updated results of a phase 1 study
https://esmocongress.esmo.orgOutcomes with trifluridine/tipiracil plus bevacizumab across age groups in metastatic colorectal cancer: The BeTAS study
https://esmocongress.esmo.orgBiweekly versus conventional trifluridine/tipiracil plus bevacizumab for refractory metastatic colorectal cancer: The pragmatic phase 3 PRABITAS trial
https://esmocongress.esmo.orgFinal overall survival (OS) results from BEATcc (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030), a randomised phase 3 trial of first-line atezolizumab (atezo), chemotherapy (CT) and bevacizumab (bev) for metastatic, persistent or recurrent cervic
https://esmocongress.esmo.orgSource: Arndt Vogel · x.com